A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 10 Oct 2022 Status changed from active, no longer recruiting to completed.
- 09 Sep 2022 Planned End Date changed from 1 Sep 2022 to 8 Sep 2022.
- 09 Sep 2022 Planned primary completion date changed from 1 Sep 2022 to 8 Sep 2022.